Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- Cost Comparison Standard
- ID number:
- 6378
Provisional Schedule
- Expected publication:
- 05 November 2025
Project Team
- Project lead
- Vonda Murray
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Peninsula Technology Assessment Group (PenTAG), University of Exeter
Stakeholders
- Companies sponsors
- Johnson & Johnson Innovative Medicines (abiraterone originator)
- Sandoz (abiraterone)
- Others
- Department of Health and Social Care
- Health Technology Wales (HTW)
- NHS England
- Patient carer groups
- Prostate Cancer Research
- Prostate Cancer UK
- Tackle Prostate Cancer
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- NONE
- Comparator companies
- AstraZeneca UK (bicalutamide, goserelin) signed, participating
- Bayer (darolutamide) signed, participating
- Janssen-Cilag (apalutamide) signed, participating
- Accord (docetaxel, bicalutamide, relugolix) not signed, not participating
- Astellas (enzalutamide) not signed, not participating
- Dr Reddy’s (docetaxel) not signed, not participating
- Hospira (docetaxel) not signed, not participating
- Ipsen (triptorelin) not signed, not participating
- Medac UK (docetaxel) not signed, not participating
- Orion Pharma UK (histrelin) not signed, not participating
- Sanofi (docetaxel) not signed, not participating
- Seacross (docetaxel) not signed, not participating
- Sunpharma (bicalutamide) not signed, not participating
- Takeda UK (leuprorelin) not signed, not participating
- Zentiva (bicalutamide) not signed, not participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 28 April 2025 | Invitation to participate |
| 01 April 2025 - 15 April 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6378 |
| 01 April 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 01 April 2025 | In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual